Company intelligence / Profile preview

Fytozimus Biotech

Ownership: Private
Development stage: Commercial

Overview

Fytozimus Biotech develops and markets natural enzymes for the dairy industry. The company has launched novel milk-clotting enzymes enabling cheese production from non-traditional milks like camel or goat milk and low-fat/skimmed cow's milk. Their products are positioned as natural alternatives to traditional rennet or chemical coagulants.

Therapeutic areas: Other
Modalities: EnzymeProtein
Industry: Non-Drug Biotech

Drug pipeline

1 asset

lactase

Commercial

Indications: Lactose intolerance, Dairy processing

Beyond the preview

Go deeper on Fytozimus Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fytozimus Biotech.

Explore the full profile